Background: Somatic cutaneous small sensory fiber neuropathy (SSFN) can be an early manifestation of impaired glucose tolerance and diabetes mellitus and/or insulin resistance among obese subjects and is often associated with pain, wound occurrence and impaired wound healing. It is yet unclear as to whether SSFN is prevalent among obese individuals without glucose and/or insulin dysregulation despite abundant evidence of delayed wound healing. Objective: To observe whether there is hypofunctioning of stimulated capsaicin-sensitive cutaneous nerves (small sensory fibers) in obese subjects with/without hyperglycemia and hyperinsulinemia. Design, setting and participants: Fifty-eight morbidly obese and 15 lean subjects were recruited for small fiber testing of the forearm in a cross-sectional study. Hyperglycemia was observed in 35 obese subjects. Of 25 obese subjects, hyperinsulinemia was noted in 15, 14 of which were hyperglycemic. No subjects demonstrated symptoms/signs of neuropathy over the hairy skin of the forearm. In fact, a neurological examination revealed that 37 subjects were asymptomatic in the legs and only four complained of a neuropathic pain in the foot. Virtually all subjects were exposed to a set of capsaicin-sensitive tests and measures which were identified by capsaicin desensitization procedures. These tests, conducted while in a supine position in bed at the Banner Good Samaritan Medical Center, Phoenix, examined the two principle roles of cutaneous SSFs, namely conveying pain signals to the CNS and controlling local neurogenic vasodilatation (flare; axon-reflex). Main outcome measures: Heat-induced pain was assessed by verbal reports of sensation after accommodation and heat-, capsaicin-, and transcutneous stimulation-induced blood flow was measured by laser Doppler flowmetry with probes placed at the site of stimulation and 1 cm remote from the site, the latter to evaluate flare latency and intensity of flare. Results: Significant depression of pain and flare responses were observed in the obese subjects in all but one test. Decreased pain and flare responses were noted in all subjects without hyperglycemia and hyperinsulinemia. Age negatively correlated with capsaicin-induced flare in both the obese and normal groups. Conclusion: SSFN was prevalent in the cohort of morbidly obese subjects in a skin area without neurological symptoms or signs and in subjects with/without hyperglycemia and hyperinsulinemia. SSFN may be a serious factor in observations of impaired wound healing among obese subjects, a particularly worrisome problem in an obese aging population given the propensity for small fiber impairment in aging subjects. Small fiber impairment in the younger obese population may signal an early aging phenomenon.
Introduction
The past quarter century has witnessed a dramatic increase, now reaching epidemic proportions, in the prevalence of a cluster of inter-related metabolic disease states that are associated with obesity, for example, insulin resistance, impaired glucose tolerance, Type 2 Diabetes, and hyperlipidemia. Obesity-related disorders kill some 300 000 persons each year. This trend is worsening, particularly in North America where the prevalence of overweight adults has increased by more than 50% in the past decade. Without question, chronic diseases associated with obesity and diabetes represent a heavy and growing burden to society in terms of both direct medical costs and significant morbidity and mortality rates. 1 Central to the disease states associated with glucose/ insulin dysregulation is the role of the small diameter cutaneous primary afferent neurons, comprised of both myelinated (Ad) and unmyelinated (C) nociceptors. Although they are the largest group of primary afferent neurons in human cutaneous nerves, 2 they cannot be assessed by the quantitative measures routinely used to evaluate large fiber neuropathy such as vibratory threshold, nerve conduction and sensory latency tests. 3 Descriptions of small fiber neuropathy usually implicate impairment of both somatic and sympathetic nerves. 3, 4 However, this paper limits its focus to somatic small fiber neuropathy (SSFN), specifically cutaneous nociceptors. SSFN is well known as a common disorder in both pre-diabetes, that is, impaired glucose tolerance (IGT) 5 and in fully developed diabetes. 6, 7 Sumner et al. 7 claim that it is the small nerve fibers that are notably impaired in IGT, whereas both small and large fibers are affected in diabetes. Indeed, small nerve fibers may offer the earliest detectable sign of impending neuropathy in persons with glucose dysmetabolism and/or with insulin resistance. 8 The involvement of small fibers before large fibers is confirmed in nerve biopsy studies which found a predominant loss of Ad and C fibers earlier than the loss of large myelinated (Aa, Ab) fibers. 9 Ziegler et al. 10 observed that the most frequent abnormality among asymptomatic and symptomatic (painful neuropathy) diabetic subjects was an elevated threshold for thermal sensation in the foot, a sign of small fiber dysfunction. It must be emphasized that although small fiber neuropathy was often associated with neuropathic symptoms like paresthesias and pain, many people were asymptomatic. Lacomis 3 and others have found that some forms of SSFN do not necessarily follow a 'dying-back process' with length-dependency (distal to proximal) progression with duration of diabetes; they may be diffuse, multifocal or generalized. 4 The Ad-and, more so, C-fiber primary afferent neurons involved in SSFN are notably nociceptors responding to noxious mechanical, thermal, and irritant chemical stimuli; but they can also be excited by non-noxious stimuli such as heat and transcutaneous electrical stimulation. [11] [12] [13] [14] [15] Although C-fibers convey pain signals to the CNS, they also have an 'efferent, or effector' function. Under normal physiological conditions, 16 C-fibers control vasodilatation of the skin microvasculature (arterioles), mediating axonreflexes locally 17 and/or centrally (dorsal root reflexes 18 ) by release of neuropeptides (e.g., calcitonin gene-related peptide, CGRP) from the terminals of the nociceptive afferents. 19 As a consequence, microcirculatory impairment at least in the upper extremity is related to the dysfunction of small fiber neuron, 4 without coexisting microangiopathy. 4, 20 This exists in obese subjects with hyperglycemia, hyperinsulinemia and insulin resistance without hyperglycemia, as well as in obese subjects without insulin and glucose dysregulation. 8, 20 To test the function of small somatic (not sympathetic) nerve fibers, 21, 22 capsaicin, a naturally occurring pungent ingredient of chili peppers, has been applied acutely to the skin. Corresponding to the concentration, topical capsaicin causes spontaneous burning pain, sensitization and a hyperemia or 'flare' reaction; later, following chronic administration, nociceptor desensitization occurs. 21 Most likely, this is due to the human epidermis containing a high density of capsaicin (vanilloid or TRPV1) receptors and axons labeled with the pan-neuronal marker, protein gene product (PGP 9.5). [23] [24] [25] This suggests that the epidermis is rich in capsaicin-sensitive nerves.
In skin, these capsaicin-sensitive nociceptive afferents play a significant role in sensory function, particularly a nocifensor role 17 in tissue protection due to their ability to: (1) convey pain signals to the CNS upon stimulation by noxious mechanical, thermal and irritant chemical stimuli; (2) elicit a pruritic reaction; 26 (3) cause sensitization of the skin (e.g., to
heat) decreasing the pain threshold, a process defined as primary hyperalgesia 22, [27] [28] [29] [30] (4) evoke an axon-reflex flare or neurogenic vasodilatation. 21, 31, 32 All four of these reactions, acute heat pain, pruritis, sensitization and flare reactions, are C-fiber mediated, apparently by utilizing different sub-sets of C-fibers. 15, 33 Specific noxious and non-noxious stimuli are applied to the skin to activate nociceptive afferent neurons to induce a spreading hyperemia, which is visible as a neurogenic vasodilatory, or flare, response. 12, 21, 31, 32, 34 Assessment of the axon-reflex flare by noxious heat-and capsaicinstimulation and by non-noxious transcutaneous electrical stimulation can be used to measure C-fiber function. 35, 36 While objective measurement of the flare reaction can be accomplished by visual assessment, introduction of laser Doppler flowmetry (LDF) has made it possible to monitor the flare response continuously in a small area of the skin, thereby facilitating the study of the axon-reflex in terms of flux. Continual exposure to topical capsaicin leads to desensitization of nociceptive afferent neurons and, thus, increases the heat pain threshold and virtually abolishes the neurogenic vasodilatory response to noxious mechanical, thermal or irritant chemical stimulation as well as to non-noxious stimulation. 8, 21, 22, 34 Such outcomes provide evidence that these tests can be used to assess the function of C-fibers and SSFNs. Capsaicin-induced desensitization is ascribed to morphological damage of Epidermal Nerve Fibers (ENFs) which contain a high concentration of nociceptive afferent neurons. 37 In a recent abstract, 20 we presented data from a small number of morbidly obese subjects with or without hyperglycemia and/or hyperinsulinemia. Almost all subjects showed a profound SSFN in capsaicin-sensitive tests of pain and flare as described in another abstract. 11 Functional impairment of small fibers was observed in both the forearm and thigh to the same degree, suggesting that the SSFN was a generalized phenomenon. 4, 20 Subsequently, a larger population of morbidly obese subjects was studied using a similar protocol. The results of this study are presented in the following sections, further supporting the view that obese subjects with or without hyperglycemia and/or hyperinsulinemia demonstrate SSFN.
Methodology

Subjects
After the study protocol and informed consent were approved by the Institutional Review Board of the Banner Good Samaritan Medical Center, 15 normal and 58 morbidly obese subjects were recruited. The morbidly obese subjects had a BMI 435 and a waist/hip ratio consistent with visceral obesity. Table 1 lists the population characteristics. The normal subjects were excluded if they exhibited hyperglycemia, hyperinsulinemia, sleep apnea or tobacco use, whereas obese subjects were accepted with various conditions related to the metabolic syndrome. Peripheral vascular disease or an ankle-brachial index of o0.9 were cause to exclude any subject. All qualified subjects received a clinical neurological examination of the peripheral nervous system of the upper and lower extremities conducted by RMH.
Cutaneous blood flow measurement
Cutaneous blood flow was measured using a DRT 4 Laser Doppler Flowmeter system (Moor Instruments, Devon, UK). A fiber optic probe directed laser-generated light of a wavelength of 780-820 nm to the skin surface. As the light reflected from moving blood cells, it underwent a shift in frequency (Doppler Effect) that is dependent on the number and velocity of the moving blood cells. Blood flow was measured in arbitrary units (AU). The probe was placed into a recess in the center of a stimulating chamber (e.g., perspex, thermode) to measure 'direct flow' and in a recess 10 mm outside the edge of the stimulator to measure 'indirect flow' or the axon-reflex. This probe configuration was used for all tests. Direct and indirect flow was measured under three modes of stimulation: heat via a contact thermode, topical capsaicin application via a passive iontophoretic chamber, and transcutaneous electrical stimulation via an active iontophoretic chamber.
Protocol
Experiments were conducted in a 24-261C room with the subject reclined in a hospital bed with one or two pillows under the head. Right and left forearms were tested alternately with the stimuli being placed aside any prior hyperemic skin. The hairy skin of the proximo-lateral forearm was continually cleansed with an alcohol swab. Before each test, 60 s of baseline temperature and blood flow were recorded. These values were subtracted from peak blood flow values to yield a 'net' flux, the value reported in the Results section.
Heat stimulation
Before testing, each subject underwent a training trial to ensure their prompt verbal report of the various sensations accompanying rising temperature (e.g., warm, itch, hot, burn). Heat was delivered by a circular brass contact thermode (10 mm diameter) centered in a 35 mm stabilizing collar placed on the forearm. A probe was placed in the center of the thermode and a second probe was placed 1 cm from the thermode. Two forms of stimulation were used: heat-ramp and heat-step.
In the heat-ramp procedure, the thermode temperature was fixed at 321C for 1 min followed by a 25 s ramp to 441C that was then maintained for 20 min. 38 The subject reported continuously on perceived sensations. The time of each report and the maximum net hyperemic response as determined by LDF were recorded. Prevalence of somatic small fiber neuropathy in obesity RM Herman et al
In the heat-step procedure, basal blood flow was monitored at resting skin temperature and later at 321C. The temperature was raised in increments of 21C per minute until a maximum temperature value of 481C was reached. Sensory responses (specifically, heat pain threshold, HPT) and peak net flows at each increment were documented.
A second heat-step test immediately followed an acute application of topical capsaicin to the skin to measure sensitization by HPT, that is, primary hyperalgesia. 27, 29 Two normal and obese subjects complained that the pungency from the capsaicin was extreme and, as a consequence, the heat-step test for hyperalgesia was not conducted.
Topical capsaicin
Capsaicin, 8-methyl-N-vanillyl-6-nonenamide, is a vanilloid neurotoxin that targets somatic small primary afferent neurons. 34 Capsaicin (1% in 75% ethanol, 25% saline) was applied topically for 45 min through a central chamber (300 ml capacity, 1 cm diameter) in a clear circular plastic perspex adhered to the skin. Throughout the application, perceptual responses and peak flow values were obtained. The vehicle was applied at different skin sites to six normal subjects.
Transcutaneous electrical stimulation A non-noxious, constant cathodal current was delivered by a platinum ring electrode in a central iontophoretic chamber. The central reservoir of the iontophoretic chamber was filled with methylcellulose (2%), an inert vehicle used with other vasoactive compounds for iontophoretic drug delivery. An indifferent electrode was applied to the wrist. Progressive increases in current dose (millicoulombs, mC) were delivered using a current of 0.2 mA applied for 10, 20, 40, 80 and 160 s. These represented doses of 2, 4, 8, 16 and 32 mC. A poststimulus interval of 180 s followed each of the first four doses; a 240 s interval followed the highest dose. Peak flow at the end of each stimulus period was recorded.
Capsaicin-induced desensitization
Eight normal subjects were recruited to ascertain the degree of capsaicin sensitivity of each of the tests described above. Each subject applied topical capsaicin to one forearm and thigh, and the vehicle to the opposing limb in 45 min applications, three to four times daily for 5 days. The results of these experiments suggest that all tests revealed capsaicin sensitivity as presented, in-part, in Figure 1 .
Statistical analysis
Group mean data for continuous variables, such as blood flow, temperature and latency were compared using unpaired t-tests (HPT, flare, latency) and one-way analysis of variance with Tukey's post hoc multiple comparison tests for differences in dose response curves (electrical stimulation). Data for individual participants were standardized for each dependent variable using Z-scores, and Pearson's R 2 correlation values with 95% confidence interval were used to detect relationships between variables. All statistical analyses were performed by means of SPSS statistical software (version 11.5.0). Statistical significance was determined by a twotailed assessment. Standard errors of the mean (s.e.m.) are indicated in Table 2 and by the error bars in all graphs. All P-values were designated within the figure (n.s. ¼ P40.05). Prevalence of somatic small fiber neuropathy in obesity RM Herman et al obese subjects. Of the 25 obese subjects, 15 were hyperinsulinemic, 14 of which were also hyperglycemic (IGT ¼ 9; DM ¼ 6). Hyperglycemia was noted in 35 obese subjects and none of the normal subjects. Of these 35 obese subjects, 14 were IGT and 21 were DM. Please note that 40% of the normal subjects revealed hyperlipidemia. The neurological examination of 55 obese subjects revealed the following: 25 had no symptoms or signs of neuropathy; 11 reported no symptoms but demonstrated small fiber impairment; one reported no symptoms but showed large and small fiber impairment; two groups of seven reported non-painful symptoms, usually in the foot, with either involvement of small fibers only or large and small fibers; four reported painful feet associated with small and large fiber neuropathy. There were no symptoms or signs of neuropathy over the area of skin tested.
Results
Demographics
Capsaicin-induced desensitization
Topical capsaicin was applied to normal subjects (n ¼ 8) three to four times daily for 5 days.
11 When compared with the action of the vehicle alone, capsaicin-induced desensitization (Cap-D) to heat, acute capsaicin and transcutaneous electrical stimulation was pronounced for each stimulus based upon the following observations:
1. HPT increased to greater than the maximum temperature utilized (481C). 2. During the heat-ramp test, heat-induced flux decreased significantly under the thermode (direct flow) and also outside the thermode (indirect flow). (Figure 1a ). 3. An acute capsaicin challenge produced no pungency and virtually no increased blood flow (not illustrated). Acute effects of capsaicin Quality of sensation. Using the criteria for capsaicin-induced pungency created by Green and Shaffer, 26 normal subjects reported a 90% pungency level with approximately 80% perceiving burn/pain and 20% reporting a stinging/prickly sensation. Obese subjects reported only a 45% pungency level described as burn/pain in all but one subject and a longer latency to a pungent effect (Figure 2a ). Six subjects did not perceive any change in sensation (e.g., itch, warm). In normal subjects pungency and flare were not elicited by the vehicle alone.
Blood flow (flux). (Figure 2b ) Both direct and indirect flow sites showed a capsaicin-induced peak flow that was significantly lower in obese subjects compared to normals. The mean peak direct and indirect flow values for the normal and obese subjects are depicted in Table 2 .
Latency to flare. (Figure 2c ) Both direct and indirect flow sites showed a capsaicin-induced vasodilatory response latency that was significantly delayed in obese subjects compared to normals. The mean latency for direct and indirect flows is described in Table 2 . Thirty-one obese subjects demonstrated prolonged latencies (e.g., 420 min) to the flare response, that is, 42 s.d. from the normal mean. Among these 31 subjects, 20 did not report pungency. Furthermore, 18 subjects revealed very low flow amplitudes, defined as a flux o100. Eleven subjects demonstrated flare latency at or near the maximum exposure time of 45 min or not at all. Of these 11 subjects, eight reported no pungency. The normal subjects exposed to the vehicle did not demonstrate a delayed response. Figure 2d depicts a significant (Po0.001) negative correlation between flux (indirect flow) and latency to the flare with a correlation coefficient of R 2 ¼ 0.401. Prevalence of somatic small fiber neuropathy in obesity RM Herman et al Capsaicin-induced hyperalgesia to heat. Capsaicin caused a marked primary hyperalgesic response to heat in both the normal and obese populations ( Figure 3 , Post-Cap). Both groups demonstrated a significant fall (Po0.001) in the HPT with an average of B71C (see Table 2 ). Approximately 80% of the obese population (n ¼ 43/53) and 90% of the normal population (n ¼ 11/13; two complained of excessive pain before the heat probe could be applied) demonstrated a pronounced hyperalgesic response of 5-161C. Of nine obese subjects who demonstrated a HPT at the peak temperature or did not report pain, all but one revealed a long latency/low amplitude blood flow response to acute capsaicin application.
Responses to heat-step and heat-ramp increases Heat-step increases.
Step increases in heat every 21C from 32 to 481C were associated with a significantly (P ¼ 0.007) Figure 3 Prior to capsaicin application (Pre-Cap), the HPT to a step-increase in temperature was significantly raised in the obese group. Following capsaicin (Post-Cap), the HPT was significantly (Po0.001) lowered in both groups, indicating primary hyperalgesia.
Prevalence of somatic small fiber neuropathy in obesity RM Herman et al increased HPT in the obese group (Table 2 and Figure 3 Pre-Cap).
Heat-ramp increases. A heat-ramp stimulus from 32 to 441C (at an average speed of 21C/s) caused a significant reduction in flare intensity of 450% (Figure 4) , whereas there was no significant difference between the two groups when comparing blood flow responses at the direct site (Table 2 ; Figure 4 ). While the flare reactions were profoundly impaired, perceptual reports from obese subjects indicated that B45% claimed 'pain/burn' sensation to or at 441C, a value similar to that of the normal subjects. Approximately 15% (n ¼ 8) of the obese subjects had no change in sensation.
Dose-response relationships during transcutaneous electrical stimulation Dose (mC)-response (flux) curves were obtained during incremental increases in duration of stimulation at the same current intensity (0.2 mA). In both groups, direct and indirect flux increased as a function of current dose. Increasing charge or dose (mC) was associated with significantly lower flux at each dose in the obese group at both direct (not illustrated) and indirect sites ( Figure 5 ).
Correlations with BMI, age and hyperglycemia
Pearson's correlation coefficients were used to examine the relationships between reported pain (in terms of threshold or presence of pungency) and flare with BMI, age and hyperglycemia in each of the two groups. The only significant observation was that of age and capsaicin flare response (two-tailed, R 2 ¼ À0.114; P ¼ 0.017) for the obese group. Correlation coefficients between all other dependent variables related to capsaicin-sensitive responses did not show a significant relationship with age. Age and capsaicininduced flare for the normal group also indicated a negative correlation but the coefficient did not yield significant figures, most likely due to the small population sample. Using frequency histograms of Z-scores for each or the sum of six sets of pain/flare data (i.e., HPT before and following capsaicin application, capsaicin pungency and flare latency and magnitude, and flare magnitude with electrical stimulation), the potential role of hyperglycemia and hyperinsulinemia was analyzed. Pearson correlations did not reveal significance between fasting hyperglycemia and normoglycemia (o100 mg/dl of glucose; o5.5 HbA1C) nor between hyperinsulinemia and normoinsulinemia. Further, we used the same statistical techniques to examine whether obese subjects with (B75%)/without a metabolic syndrome (B25%) showed a difference in the correlation between the same sum of Z-scores. A Pearson correlation coefficient did not indicate a significant difference (R 2 ¼ 0.001, P ¼ n.s.).
Discussion
The application of capsaicin-sensitive tests ( Figure 1 ) to a large group of morbidly obese subjects reveals that small fiber, notably C-and Ad-nociceptor, neuropathy (SSFN) is common in this population. The following observations are indicative of functional impairment of cutaneous nociceptor activation: Additionally, a number of issues are identified:
1. Approximately half of the obese subjects were neurologically asymptomatic with very few (n ¼ 4) reporting pain, Figure 5 The conduct of the dose-response curve was similar to that described in Figure 1b in that under normal conditions, blood flow increased gradually with the magnitude of the dose and under conditions of obesity (like capsaicin-desensitization) the dose-response curve was markedly diminished.
Prevalence of somatic small fiber neuropathy in obesity RM Herman et al an unanticipated outcome given the relatively high incidence of neuropathic pain in subjects with SSFN associated with IGT and diabetes. 3, 5, 10 2. Utilization of capsaicin-sensitive tests suggests that SSFN is a generalized disorder; 4, 11, 20 in contrast, our clinical examination using heat/cold stimuli reveals a lengthdependent or dying-back process, which may imply two distinct pathological processes. 3. The presence of hyperalgesia following capsaicin treatment in subjects with obvious SSFN suggests that the thermode size was sufficient to activate some nociceptors, including presumably 'silent' nociceptors (e.g., mechanoinsensitive nociceptors), which would lead to summation of impulses by central neurons to cause pain (neurogenic hyperalgesia). 13, 27, 28, 30, 39 4. If depressed blood flow measured under the thermode ('direct flow') during a heat-ramp test can be assumed to be an indicator of microangiopathy, 38,40 obese subjects do not reveal a microangiopathic process (at least in the upper extremity) to account for the microcirculatory changes observed with capsaicin treatment and electrical stimulation. 4, 20 5. Hyperglycemia (IGT, diabetes) is a potential contributing factor in SSFN among the obese subjects but only B70% were considered hyperglycemic (a 2-h post-prandial test might prove more useful). A potential causative factor is oxidative stress which is raised in obesity, diabetes, insulin resistance and neuropathy. 41 Antioxidant therapy may improve nerve pathophysiology and, hence, reduce positive neuropathic sensory symptoms (e.g., pain).
Sir Thomas Lewis in 1937 12, 17 postulated that nerves responsible for the axon-reflex (now identified as C-and Ad-nociceptors) are associated with local defenses against injury (inflammation). 34 He called these nerves 'nocifensor nerves', which implied that they elicited protective reactions such as hyperalgesia and flare responses to injury. Neurons participating in the local axon-reflex are considered peptidergic; the candidate peptide, thought to be released at the terminal endings of small nerve fibers, is CGRP. 19 Although a distinct system of nerves, namely nociceptors, generate signals which mediate acute and hyperalgesic pain and flare, pain and flare are not necessarily functionally coupled. 15 For example, excitation of C-fiber discharges need not be associated with pain sensation but can evoke a flare response. [11] [12] [13] [14] The two may have different sensory/efferent pathways, and/or different sub-sets of nociceptors. 15, 33 The difference in the flare and pain response to a heat-ramp stimulus among the normal and obese subjects may be indicative of such a dissociation and, in fact, would favor a concept that the organism attempts to elicit an early protective reaction (neurogenic vasodilatation) at a temperature (441C) just below that which will become injurious to tissue.
14 Flare can be suppressed or abolished by denervation, 21, 42 local anesthetics, 12,21 capsaicin-desensitization, 22 ,34 disease (diabetes, post-herpetic neuralgia), 21, 43 and aging. 32 Under circumstances of prolonged depression of small fiber function, tissue integrity can be substantially impaired. Animals and humans with suppressed C-fiber function are at high risk for wound occurrence and impaired wound healing. 44 An intact nociceptor system of primary afferent neurons, for example, capsaicin-sensitive nerves, is important in the initiation of the inflammatory process and successful tissue repair. 44, 45 Hence, our study suggests that obese subjects with/without diabetes would be at risk for impaired wound healing. Indeed, the presence of a dysfunctional nociceptive system among obese subjects may be a critical factor in their often observed failure of wound healing. 46 Although the obese subject may demonstrate a weakened flare reaction, sufficient blood flow may be attained (perhaps due to vascular receptor upregulation) to ensure or enhance tissue integrity as revealed by observations of diabetic pressure ulcer improvement treated by transcutaneous electrical stimulation, TENS. 47 Wound healing can also be enhanced by the exogenous application of peptides. CGRP has been used experimentally in animals 44, 48 and humans to promote enhanced rate of wound healing. 49 Age is an important determinant of the strength of nociceptive function. Aging animals demonstrate reduction in the number of C-fibers which is associated with decreased noxious thermal sensitivity and reduced flare responses. 44, 50 The latter reaction is particularly observed after chronic capsaicin treatment in young animals as well as among aged animals. In a sense, this connotes a premature depletion of nociceptive afferents in the young animals when treated with capsaicin, a most likely event in the obese population. In normal subjects, Helme 32 recognized a negative correlation between capsaicin-induced flare magnitude and size with age. Similarly, both of our populations revealed a negative correlation between capsaicin-induced flare magnitude with age. Age-related loss of ENFs has also been reported. 51 As an intact nociceptor system of primary afferent neurons with their sensory neuropeptides is an essential prerequisite for prevention of wounds and wound healing, 44 ,50 the anticipated outcome would be increased prevalence of wounds and delay in healing among the aged population. 52 Given that nociceptive function is likewise impaired in younger obese subjects, there would be a significant risk of failure to heal. Chang et al. 53 report a higher complication rate for surgical flaps and donor sites in obese subjects, which is a similar outcome observed in animals after small sensory fiber denervation with capsaicin. 45 Under these conditions, the rate of wound healing can be augmented by the application of TENS and/or exogenous peptides, such as CGRP, which are sufficient to evoke a flare reaction without a concomitant sensory response, that is, pain perception. 47, 49 In summary, we have observed that morbidly obese subjects demonstrate significant SSFN when challenged with tests considered to be capsaicin-sensitive and, hence, a measure of small primary afferent neuron function. This Prevalence of somatic small fiber neuropathy in obesity RM Herman et al disorder is viewed as a generalized, largely asymptomatic process (despite a relatively high number of IGT and DM subjects) with a likely pathophysiologic mechanism concerned with oxidative stress. 41 As in diabetes, 4 SSFN in obesity mimics the aging process in which C-fibers are particularly vulnerable, but the generalization of the functional impairment varies with the clinical presentation (dying-back) suggesting two distinctly different pathological processes. Perhaps the latter is related to hyperglycemia with/without insulin resistance. We present the argument that SSFN observed in obesity is a similar process to that of age-related decrease in modulation of skin vascular reactivity by sensory nerves. Future studies will address the relationship between small fiber function and density of epidermal nerve fibers; preliminary results from skin punch biopsies reveal a marked reduction in epidermal nerve fiber density among the obese population, further supporting the notion of a neuropathic process (unpublished observations). In addition, there will be a need to improve our diagnostic capacity for insulin resistance and DM/IGT, assessing the role of oxidative stress, and the study of the temporal pattern of development of somatic small fiber neuropathy. Whether SSFN should be considered an entity within the many factors comprising the metabolic syndrome or should be considered part of a continuum across factors needs to be determined, that is, impairment of small fiber neuronal function may be viewed as a primary defect which can be inherited (but is probably acquired) a contributing factor among the metabolic syndrome entities, or an epiphenomenon within the range of metabolic syndrome deficits.
